Paul Van Slyke

PharmaDrug Advances DMT-Analogue Program For Glaucoma

PharmaDrug Inc. (OTCQB: LMLLF) (CSE: PHRX) in collaboration with the Terasaki Institute for Biomedical Innovation, has successfully completed the fabrication of a novel medical device capable of delivering sustained, low quantities of undisclos

PharmaDrug Posts Positive Results For DMT-Analogue Program To Treat Glaucoma

Psychedelics and cannabis-focused pharmaceutical company PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) has completed a head-to-head potency comparator study of its two undisclosed DMT-analogue candidates for the treatment of primary open angle glaucoma.